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Abstract
Docetaxel (DTX) is a very important member of taxoid family. Despite several alternative delivery systems reported
recently, DTX formulated by Polysorbate 80 and alcohol (Taxotere
®) is still the most frequent administration in
clinical practice. In this study, we incorporated DTX into Polysorbate 80/Phospholipid mixed micelles and
compared its structural characteristics, pharmacokinetics, biodistribution, and blood compatibility with its
conventional counterparts. Results showed that the mixed micelles loaded DTX possessed a mean size of
approximately 13 nm with narrow size distribution and a rod-like micelle shape. In the pharmacokinetics
assessment, there was no significant difference between the two preparations (P > 0.05), which demonstrated that
the DTX in the two preparations may share a similar pharmacokinetic process. However, the Polysorbate 80/
Phospholipid mixed micelles can increase the drug residence amount of DTX in kidney, spleen, ovary and uterus,
heart, and liver. The blood compatibility assessment study revealed that the mixed micelles were safe for
intravenous injection. In conclusion, Polysorbate 80/Phospholipid mixed micelle is safe, can improve the tumor
therapeutic effects of DTX in the chosen organs, and may be a potential alternative dosage form for clinical
intravenous administration of DTX.
Introduction
As the most successful chemotherapeutic drugs cur-
rently available, Taxanes play an important role in the
treatment of various solid tumors [1]. As a second-gen-
eration semi-synthetic taxane derivative, docetaxel
(DTX) is about twice as potent as paclitaxel in inhibiting
microtubule depolymerization, and has the unique abil-
ity to alter certain classes of microtubules [2], which dif-
fers from most spindle poisons currently used in clinic.
However, the clinical intravenous administration of
commercially available DTX (Taxotere
®) is formulated
in a highly concentrated solution containing 40-mg
DTX and 1040-mg Tween
® 80 (Polysorbate 80) per mL.
This concentrated solution has to be carefully diluted
with solvent containing 13% ethanol in saline before
administration, and has to be used within 4 h for its
limited stability. These shortcomings bring great incon-
venience to the practical application.
As a result, current research is mainly focused on
developing new preparations of DTX to improve the
therapeutic index and reduce the adverse reactions [3].
Various drug delivery systems have been reported
recently, such as DTX loaded nanoparticles [4], lipo-
somes [5], N-palmitoyl chitosan anchored DTX lipo-
somes [6], self-emulsified DTX [7], PEGylated liposomes
[8], PEGylated immunoliposomes [9], and PEG-lipo-
somes-folic acid bioconjugates [10]. Although they have
their advantages, respectively, each of the above is ham-
pered by one or more problems, such as complicated
preparation process, high cost, and low stability of the
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® is still the most
widely used clinical DTX preparation currently available.
Increasing evidence highly suggest that when drug is
incorporated into different carriers, its pharmacokinetics
may be completely altered. Therefore, there is an urgent
need for a pharmaceutical composition comprising
DTX, which should have high solubility and stability,
simplified preparation process, and the same pharmaco-
kinetics as Taxotere
®.
As well known, Phospholipid is an important struc-
tural component of cell membranes and a biocompatible
material with an excellent biocompatibility [11]. The
physical and chemical properties of Polysorbate/Phos-
pholipid mixed aggregates have been report previously
[12]. In our previous report, we optimized the condi-
tions to prepare DTX-loaded Polysorbate 80/Phospholi-
pid mixed micelles based on the preparation of
Taxotere
®, revealed the efficient and stable encapsula-
tion of DTX in the mixed micelles by using the self-
assembly method [13,14], and demonstrated the mixed
micelles can prolong the stable time of DTX injection to
3d a y s .T h ep r i m a r ya i mo ft h ep r e s e n ts t u d yi st o
further evaluate the characteristics of the DTX-loaded
mixed micelles, and pharmacokinetics, tissue distribu-
tion, and blood compatibility. This may provide new
idea for solving the problems faced by Taxotere
® such
as the complicated steps of clinical preparation, inaccu-
rate dosage, and low stability of the preparation.
Experimental
Materials
Phospholipid was provided by Taiwei Pharmaceutical
Factory (Shanghai, China, Mn = 760.08). Polysorbate 80
was purchased from Shanghai Shenyu Pharmaceutical &
Chemical Co. Ltd (Shanghai, China, Mn = 1309.65).
DTX (99.4%) was obtained from Shanghai Junjie Bio-
Engineering Co. Ltd. (Shanghai, China, Mn = 807.88).
Heparinsodium injection, 10,000 IU/mL was purchased
from Shanghai No. 1 Biochemical Pharmaceutical Co.
Ltd. (Shanghai, China). Glucose solution 5% was
obtained from Shanghai Baite Medical Product Co. Ltd.
(Shanghai, China). Spectra-grade reagents were used as
the mobile phase in high-performance liquid chromato-
graphy (HPLC) analysis, and all other reagents were
analytical grade and used without further purification.
Distilled and deionized water was used in all
experiments.
Animals
Male Sprague-Dawley (SD, 8 weeks old, 200 ± 20 g) rats
and female Kunming strain mice (8 weeks old, 20 ± 2 g)
were obtained from Second Military Medical University
of Chinese PLA. All the pathogen-free animals were
acclimatized at a temperature of 25 ± 2°C and a relative
humidity of 70 ± 5% under natural light/dark conditions
for at least 24 h before dosing. The experiments were
carried out in compliance with the National Institute of
Health Guide for the Care and Use of Laboratory
Animals.
Preparation of DTX-loaded Polysorbate 80/Phospholipid
mixed micelles
DTX-loaded Polysorbate 80/Phospholipid mixed
micelles were prepared by means of the self-assembly
method as we described previously [15]. Briefly, the
response surface methodology was used to optimize the
preparation of the mixed micelles: DTX (5 mg), Polysor-
bate 80 (125 μL), and Phospholipid (30 mg) were dis-
solved in 0.3 mL of dehydrated ethanol with the help of
stirring at room temperature, then the homogeneous
phase was injected rapidly into the 5% glucose solution
in order to obtain a clear mixed micelle solution with a
final volume of 10 mL, then the mixed micelles solution
was filtrated through a 0.22-μm pore-sized membrane
for further investigation. The final concentration of
D T Xi s0 . 6 2m M ,P o l y s o r b a t e8 0i s1 0 . 1 6m M ,a n d
Phospholipid is 3.95 mM.
The mean diameter and particle size distribution of
the DTX-loaded Polysorbate 80/Phospholipid mixed
micelles were determined by a particle-size analyzer
(Mastersizer 2000, Malvern Instruments, Ltd., Malvern,
U.K.), based on the laser dynamic light scattering tech-
nique. Sample solutions filtered through a 0.22-μm filter
membrane were transferred into the light scattering
cells. The intensity autocorrelation was measured at a
scattering angle of 90° at room temperature. The mor-
phological examination of micelles was performed using
a JEOL JEM-2010 transmission electron microscope
(TEM) at an acceleration voltage of 120 kV. In practice,
one drop of solution with the sample was placed on a
400-meshes copper grid precoated with a carbon film
and allowed to dry further for 30 min, then examined
with the electron microscope.
An aliquot of DTX-loaded Polysorbate 80/Phospholi-
pid mixed micelles was treated with four times volume
of dehydrated ethanol to disrupt the micelle structure.
Level of encapsulated DTX was measured using a
reverse phase HPLC method. Stock solutions of DTX
(0.2 mg/mL) were prepared by dissolving 10 mg of DTX
in 10 mL dehydrated ethanol, followed by addition of 40
mL distilled water, and standard curve was set up with
satisfactory linearity. The HPLC system consisted of a
HP HPLC (3D) series equipped with G1322A online
degasser and G1311A quaternary pump (Agilent Tech-
n o l o g i e s ,P a l oA l t o ,C A ,U S A )w a su s e d .C h r o m a t o -
graphic separations were achieved using a Diamonsil
C18 column (5 μm, 250 × 4.6 mm, Dikma Technologies
Inc, Lake Forest, CA, USA) at 25C. The mobile phase
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trile [45:55 (V/V)]. The samples were delivered at a flow
rate of 1 mL/min and detected at 230 nm using
G1314A VWD detector (Agilent Technologies, Palo
Alto, CA, USA).
Pharmacokinetic study
Sprague-Dawley rats were used to examine the pharma-
cokinetics of DTX encapsulated in Polysorbate 80/Phos-
pholipid mixed micelles. Rats were randomly divided
into following two groups (n = 6, half male and half
female): (1) DTX encapsulated in Polysorbate 80
micelles (75 mg/m
2); (2) DTX encapsulated in Polysor-
bate 80/Phospholipid mixed micelles (75 mg/m
2). Drugs
were intravenously administrated trough the tail vein.
The blood samples (0.5 mL) were collected into hepari-
nized tubes via the femoral vein at 5, 15, 30 min, 1, 2, 4,
6, 8, and 12 h. The plasma was obtained by centrifuga-
tions at 900 × g for 10 min. Plasma samples were frozen
and maintained at -20°C before analysis.
Tissue biodistribution study
To assess the effect of Polysorbate 80/Phospholipid
mixed micelle formulation of DTX on tissue distribu-
tion, 72 female Kunming strain mice were randomly
divided into two groups. The administration protocol of
tissue distribution study was as same as that used in the
pharmacokinetics. At 5, 15, 30 min, 1, 2, 3, 4, 6, and 8 h
after drug injection, each animal (n =4f o re a c ht i m e
point) was euthanized and heart, spleen lung, liver, kid-
ney, uterus and ovaries, brain as well as blood samples
were collected. Tissue samples were blotted with paper
towel, rinsed in ice-cold saline, blotted to remove excess
fluid, weighed, and stored at -50°C until required for
analysis.
Aliquots of 0.1 g tissue samples were minced into
small pieces (1 mm
3 on average), homogenized in the
mixed solution of acetonitrile and water (50:50, V/V)
with a ultrasonic Cell Disrupter System (JY92-, Ningbo
Scientz Biotechnology Co., Ltd, Ningbao, China), and
vortexed for 1 min. After centrifugation at 15000 × g for
3 min, the 100-μL clear supernatant was removed and
extracted by 600-μL tert-butyl methyl ether, the organic
phase was separated and evaporated under a gentle
stream of nitrogen. Then, the residue was dissolved in
40 μL of acetonitrile, centrifuged at 1400 × g for 5 min,
and aliquots of 20 μL were injected into the HPLC sys-
tem. The concentrations of DTX in tissue samples were
determined by the HPLC method as same as the analy-
sis of the mice plasma samples.
Serum sample analysis
DTX levels in plasma and tissue were measured by
reverse-phase HPLC method. Briefly, 200 μLo fp l a s m a
was extracted twice with 200-μL tert-butyl methyl ether.
The total clear organic layer was separated by centrifu-
gation at 15000 × g for 3 min, and evaporated under a
gentle stream of nitrogen. The residue was then dis-
solved by 40 μL acetonitrile, centrifuged at 1400 × g for
5 min, and aliquots of 20 μL were injected into the
HPLC system. The rat plasma samples employed the
mobile phase consisted of HPLC grade acetonitrile,
deionized water, tetrahydrofuran, ammonium hydroxide
solution (25%), and acetic acid solution (36%)
[55:45:3:0.03:0.06 (V/V)]; the mice plasma samples
employed the mobile phase consisted of HPLC grade
acetonitrile, deionized water, and tetrahydrofuran
[55:45:4( V/V)]. All the analyses with a flow rate of 1.0
mL/min for the mobile phase, the retention time of
DTX in rat plasma samples and mice plasma samples
were approximately 10.7 and 11.2 min, respectively.
Hemolysis test
Rat blood was used to test the hemolysis effect of DTX-
loaded Polysorbate 80/Phospholipid mixed micelles.
Briefly, the fibrinogen was removed from 10 mL of rat
blood by stirring the blood with glass rod. Ten milliliters
of 5% glucose injection solution was added into defibri-
nogen blood sample, and supernatant was removed after
centrifugation at 900 × g for 10 min. The erythrocyte
pellets at the bottom of centrifuge tube were washed for
four times (centrifugation followed by re-dispersion)
with 5% glucose injection solution. Finally, after
repeated washing and centrifugation, an adequate
amount of 5% glucose injection was added to the ery-
throcyte pellets to give a 2% erythrocyte standard dis-
persion and stored at 4°C for further use. The DTX-
loaded Polysorbate 80 micelles (Taxotere
®), and DTX-
loaded Polysorbate 80/Phospholipid mixed micelles were
dispersed in 5% glucose injection solution with DTX
concentration of 0.5 mg/mL and Polysorbate 80 of
1.25%, respectively. The different amounts of micelle
solution with volume of 0.1, 0.2, 0.3, 0.4, and 0.5 mL
(NO. 1, 2, 3, 4, and 5) were added into six tubes with
2.5 mL of 2% erythrocyte dispersion in each. Then ade-
quate amounts of 5% glucose injection solution were
added in every tube to obtain a final volume of 5 mL.
Negative control (NO. 6) was 5% glucose injection, and
positive control (NO. 7) was prepared by adding 2.5 mL
of ultra- pure water into 2.5 mL of 2% erythrocyte dis-
persion instead of 5% glucose injection and micelle solu-
tion. After vortexing, the tubes were incubated at 37°C
and observed microscopically from 15 min to 1 h. Then,
the tubes were centrifuged at 900 × g for 10 min. At
last, the optical density (OD) was obtained from a fast
wavelength scanning between 200 and 1100 nm by a
UV-spectrophotometer (11000, Beijing analysis Instru-
ment Co., Ltd, Beijing, China) at 418 nm. The hemolysis
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=[ ( O D t -O D n)/(ODp -O D n)] × 100%. Here, the ODt
means the OD value of tested group, the ODn and ODp
were OD value of negative and positive control,
respectively.
Plasma protein binding test
Equilibrium retrodialysis was used to evaluate the
plasma protein binding ability of DTX captured in Poly-
sorbate 80 micelles and DTX captured in Polysorbate
80/Phospholipid mixed micelles, respectively. Firstly, 4-
mL rat plasma was full mixed with 1.2 mL micelles
solution for 0.5 h in 10 mL sealed glass cells with 120
rpm magnetic stirring at 36.5 ± 0.5°C, then precise
ultra- pure water was added into the mixed solution for
making up the loss of weight; secondly, dialysis bags
(cellulosic membranes with molecular weight cut-offs of
10000 Da; Millipore, USA) filled with 0.5 mL 5% glucose
injection were put into the sealed cells and the retrodia-
lysis was carried out for 6 h at 36.5 ± 0.5°C with 120
rpm magnetic stirring in temperature controlled water
bath. After cooling to the ambient temperature and
making up the loss of weight with ultra-pure water, ali-
quots of 200 μL plasma and resulting dialysate were
promptly recovered from the glass cells and analyzed by
HPLC method mentioned above, respectively. The per-
centage of plasma protein binding rate of DTX (B%)
was calculated as: B% =
5.2 × CoCi
0.5 × Ci +5 . 2× Co
× 100%.
The Co and Ci were the drug concentrations in the
plasma outside the dialysis bags and the dialysate inside
the dialysis bags (ng/mL). 0.5 and 5.2 means the volume
of the solution inside and outside the dialysis bags
respectively (mL).
Statistical analysis
The compartment of model was simulated by 3p87 pro-
gram (Practical Pharmacokinetic Program, 1987, China)
and the parameters of pharmacokinetics were obtained.
The calculation of AUC was based on statistical
moment theory. The pharmacokinetic parameters were
analyzed for statistical significance by unpaired Student’s
t-test. For this purpose, the level of significance was set
at a <0 . 0 5 .I nt h et i s s u ed i s t r i b u t i o ns t u d i e s ,t h eA U C
could not be determined in individual mice because of
the destructive study design.
Results
Characterization of DTX-loaded Polysorbate 80/
Phospholipid mixed micelles
In order to achieve longevity during systemic circula-
tion, the micelles must be small enough to evade detec-
tion and destruction of the reticuloendothelial system
(RES). The mean diameter and the polydispersity
coefficient (PDI) of DTX-loaded Polysorbate 80 micelles,
blank Polysorbate 80/Phospholipid mixed micelles and
DTX-loaded Polysorbate 80/Phospholipid mixed
micelles were 7.89 ± 1.97 nm and 0.234, 8.44 ± 2.34 nm
and 0.319, 13.89 ± 3.52 nm and 0.089, respectively,
which were measured by dynamic light scattering. It
could be seen that the size distribution was relatively
narrow (Figure 1). The hydrodynamic particle size of
the drug-loaded micelles is understandably larger than
the blank micelles, probably due to the incorporation of
large and bulky drug molecules (Mwo fD T X :8 0 7 . 8 8g /
mol) within the core. Moreover, the particle size of the
drug-loaded mixed micelles is larger than drug-loaded
Polysorbate 80 single component micelles, it is still
safely below 20 nm. There was no significant difference
in particle size of these three types of micelles. The
DTX-loaded Polysorbate 80/Phospholipid mixed
micelles were dispersed in pure water and the morphol-
ogy was investigated by TEM. These drug-loaded parti-
cles had a rod-like shape, which is one of the
characteristic shapes of micelle. The particle surface was
very smooth and no drug crystal was visible (Figure 2).
Pharmacokinetic study
The drug concentration of rats’ plasma was detected by
HPLC analysis, which has been validated with a linear
calibration curve in the range of 10 to 6000 ng/mL of
DTX and the correlation coefficient over this concentra-
tion range was 0.9996. The plasma concentration time
profiles of DTX in rat plasma after intravenous adminis-
tration of DTX-loaded Polysorbate 80 micelles and
DTX-loaded Polysorbate 80/Phospholipid mixed
micelles at a single dose of 75 mg/m
2 were compared
(Figure 3). The profiles showed a rapid decline in the
first 1 h (distribution phase) after dosing the two pre-
parations. Furthermore, the DTX concentration versus
time plots was obtained by means of a three compart-
mental model with the weight coefficient of 1/C
2 based
on computer program 3p87. The pharmacokinetic para-
meters are shown in Table 1 and analyzed for statistical
significance by unpaired Student’s t-test. The results of
the statistical analysis proved the pharmacokinetic para-
meters were no significant difference (P > 0.05) between
the two preparations. These data demonstrated that the
DTX in Polysorbate 80 micelles and the DTX in Poly-
sorbate 80/Phospholipid mixed micelles can achieve a
similar pharmacokinetic process in rats.
The mice’s plasma drug concentration was detected by
HPLC analysis, the calibration curve having DTX con-
centrations ranging from 50 to 30000 ng/mL for plasma
exhibited good linearity, and the correlation coefficient
over this concentration range was 0.9999. Results
showed that the plasma DTX concentration-time pro-
files observed in mice after intravenous administration
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Polysorbate 80/Phospholipid mixed micelles at a single
dose of 75 mg/m
2 were similar to the pharmacokinetic
study in rats. The time of distribution phase was short
and the concentration decreased quickly in this phase
(Figure 4). The pharmacokinetic parameters are shown
in Table 2 and analyzed for statistical significance.
Results showed all pharmacokinetic parameters were no
significant difference (P > 0.05) except K13.T h er e s u l t
suggested that the DTX in two preparations can achieve
a similar pharmacokinetic process in mice. This was in
consistent with the result of the intravenous administra-
tion in rats.
Tissue distribution study
The tissue distribution profiles of DTX after intravenous
administration of DTX-loaded Polysorbate 80/Phospho-
lipid mixed micelles to mice was investigated with DTX
encapsulated in Polysorbate 80 micelles as reference.
The standard curves of the peak area (Y) to the concen-
tration (C) for heart, liver, spleen, lung, ovary and
uterus, kidney, and brain are listed in Table 3. The cali-
brations were linear over a certain range in all biosam-
ples with a correlation coefficient (R) larger than 0.9990.
The DTX-AUC (DTX-area under curve) of the two pre-
parations in different tissues, including plasma, heart,
spleen, lung, ovary and uterus, kidney, and liver were
Figure 1 Particle size distributions of the micelles. (A) DTX-loaded Polysorbate 80 micelles; (B) Blank Polysorbate 80/Phospholipid mixed
micelles; (C) DTX-loaded Polysorbate 80/Phospholipid mixed micelles.
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Page 5 of 12Figure 2 Transmission electron microscope (TEM) photograph of DTX-loaded Polysorbate 80/Phospholipid mixed micelles (A, B, C)
and blank Polysorbate 80/Phospholipid mixed micelles (D).
Figure 3 Mean plasma concentration-time profiles of DTX after i.v. administration of a single 75 mg/m
2 dose of DTX-loaded
Polysorbate 80 micelles and DTX-loaded Polysorbate 80/Phospholipid mixed micelles to rats (Each point represents the mean ± SD of
six rats.).
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and rapidly distributed into most tissues following intrave-
nous administration of the two micelle preparations. The
DTX-AUC of Polysorbate 80/Phospholipid mixed micelles
was higher in all tissues compared to the reference. The
order in DTX-AUC from the highest to the lowest for
DTX-loaded Polysorbate 80 micelles was kidney > lung >
spleen > ovary and uterus > heart > liver > plasma. In con-
trast, the corresponding order for the DTX-loaded Polysor-
bate 80/Phospholipid mixed micelles was kidney > spleen >
ovary and uterus > lung > heart > liver > plasma, and the
DTX concentration in brain was too low to be detected.
Hemolysis test
Complete hemolysis was observed in tube of positive
control at 15 min. The solution was red clear-
diaphanous and there was no erythrocyte detected at
the bottom of the tube. The erythrocyte precipitated at
the bottom of other six tubes could be dispersed after
shaking, and the supernatant was achromatic and
transparent in the period of 1 h observation. The opti-
c a ld e n s i t yt e s tr e s u l t s( T a b l e5 )s h o w e dt h a tt h e
hemolysis rate of all the micelles is below 5%, and all
the hemolysis ratios of the Polysorbate 80/Phospholi-
pid mixed micelles were lower than Polysorbate 80
micelles. These suggested that all DTX-loaded micelles
made from Polysorbate 80 in these concentrations had
no destructive effect on erythrocyte, and the DTX-
loaded new formulation caused much gentler hemato-
lysis and erythrocyte agglutination at body temperature
compared to the marketed DTX-loaded Polysorbate 80
micelles.
Table 1 Pharmacokinetic parameters of DTX after i.v. administration of DTX-loaded Polysorbate 80 micelles and DTX-
loaded Polysorbate 80/Phospholipid mixed micelles to rats
Parameters Unit DTX-loaded Polysorbate 80 micelles DTX-loaded Polysorbate 80/Phospholipid mixed micelles P
t1/2a h 0.916 ± 0.608 0.919 ± 0.601 0.995
t1/2b h 4.901 ± 2.453 6.726 ± 1.684 0.626
K12 h
-1 4.780 ± 2.525 2.886 ± 1.551 0.179
K21 h
-1 2.544 ± 1.187 2.376 ± 1.421 0.828
K13 h
-1 0.773 ± 0.581 2.350 ± 1.577 0.095
K31 h
-1 0.190 ± 0.122 0.376 ± 0.404 0.310
K10 h
-1 2.800 ± 0.897 2.735 ± 0.891 0.908
AUC0-12 h μg∙L
-1∙h 2024.891 ± 287.679 2218.685 ± 407.753 0.379
Cl L∙h 0.038 ± 0.006 0.038 ± 0.007 0.468
n =6 .
Mean ± SD.
Figure 4 Mean plasma concentration-time profiles of DTX after i.v. administration of a single 75 mg/m
2 dose of DTX-loaded
Polysorbate 80 micelles and DTX-loaded Polysorbate 80/Phospholipid mixed micelles to mice (Each point represents the mean ± SD
of four mice.).
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The plasma protein binding rate of DTX captured in
Polysorbate 80 micelle and DTX captured in Polysorbate
80/Phospholipid mixed micelle were 86.05 ± 2.41 and
84.21 ± 2.21% (n = 3 repeats per measurement), respec-
tively, which showed that the plasma protein binding
rates of the DTX were relatively high in both Polysor-
bate 80 micelles and Polysorbate 80/Phospholipid mixed
micelles. No significant difference existed between them
(P> 0.05) (Table 6).
Discussion
To our knowledge, very little information has been pub-
lished about particle properties and solubilization ability
of Polysorbates, including Polysorbate 80. In particular,
no other detailed study has dealt with the research of
pharmocokinetics and tissue distribution of the drug
vesicles with Phospholipid and Polysorbate 80. This
made the discussion of our present results not only
more difficult but also more interesting. We have pre-
viously demonstrated the blank Polysorbate 80/Phospho-
lipid mixed micelles has a far lower critical micelle
concentration (CMC) values than the blank Polysorbate
80 micelles with pyrene fluorescence probe spectrome-
try, which means the new formulation get a more stable
particle structure and allow solubilizing more DTX than
the marketed one. According to the results of response
s u r f a c em e t h o d o l o g y ,w eo p t imized the conditions to
prepare DTX-loaded Polysorbate 80/Phospholipid mixed
micelles and revealed the efficient encapsulation of DTX
in the mixed micelles by using the self-assembly method
[15]. The acquired DTX is formulated in a highly con-
centrated mixed solution containing Polysorbate 80,
Phospholipid, and dehydrated alcohol. With 5% glucose
solution, this concentrated mixed solution can be
directly diluted to any precise concentration of DTX
according to the clinical practice requirement. As well
known, DTX filled in Polysorbate 80 micelles (Taxo-
tere
®) will precipitate within few hours, while the stabi-
lity time of DTX-loaded Polysorbate 80/Phospholipid
mixed micelles we prepared is more than 3 days. In the
current study, we investigated the characteristics of the
DTX-loaded Polysorbate 80/Phospholipid mixed
micelles further, and the real value based on research of
the blood compatibility, the pharmacokinetics, and the
tissue distribution in vivo (i.v.) compared with DTX-
loaded Polysorbate 80 micelles, which we made it simul-
taneously according to the preparation of Taxotere
® for
a better reference (see http://www.taxotere.com and
http://www.medsafe.govt.nz) [16].
As well known, the single component micelles is com-
posed of amphipathic micromolecules, so the particle
size of the single component micelles with drug filled in
is usually far smaller than most of the drug loaded car-
riers [17]. In our study, the mean diameter of DTX-
loaded Polysorbate 80 micelles was only 7.89 ± 1.97 nm.
Table 2 Pharmacokinetic parameters of DTX after i.v. administration of DTX-loaded Polysorbate 80 micelles and DTX-
loaded Polysorbate 80/Phospholipid mixed micelles to mice
Parameters Unit DTX-loaded Polysorbate80 micelles DTX-loadedPolysorbate 80/Phospholipid mixed micelles P
t1/2a h 0.682 ± 0.2088 0.634 ± 0.166 0.734
t1/2b h 15.790 ± 20.5700 5.695 ± 1.703 0.445
K12 h
-1 13.976 ± 7.9457 9.627 ± 6.878 0.440
K21 h
-1 2.198 ± 0.2320 2.739 ± 1.032 0.346
K13 h
-1 4.410 ± 1.4573 1.012 ± 0.687 0.022*
K31 h
-1 0.149 ± 0.108 0.155 ± 0.042 0.927
K10 h
-1 16.040 ± 12.268 14.245 ± 16.245 0.866
AUC0-8 h μg∙L
-1 ∙h 10466.290 ± 3122.821 11406.914 ± 5042.349 0.762
Cl L∙h 0.009 ± 0.007 0.008 ± 0.003 0.776
n = 4. Mean ± SD.
* P < 0.05, denotes significant difference between two groups.
Table 3 Standard curves, correlation coefficients, and linear ranges of DTX in mice tissue samples
Biosamples Standard curves Correlation coefficients (R) Linear ranges (ng/mL)
Heart Y = 0.0397C - 2.0823 0.9997 100-5000
Liver Y = 0.0428C - 8.8082 0.9997 100-30000
Spleen Y = 0.0417C - 3.6669 0.9996 100-10000
Lung Y = 0.0387C - 0.0056 0.9993 100-30000
Ovary and uterus Y = 0.0400C - 3.1940 0.9990 100-4000
Kidney Y = 0.0428C - 8.9972 0.9996 100-30000
Brain Y = 0.0406C - 4.1897 0.9994 100-40000
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Page 8 of 12Table 4 The AUC
a of DTX in mice (n = 4) tissues after i.v. administration of DTX Polysorbate 80 micelles injection and
DTX Polysorbate 80/Phospholipid mixed micelles injection
Tissues DTX-loaded Polysorbate 80 micelles(μg·h·g-
1)
DTX-loaded Polysorbate 80/Phospholipid mixed micelles(μg·h·g-
1)
Ratio
b
Plasma 10.466 11.407 1.090
Heart 74.263 99.451 1.339
Liver 42.081 71.695 1.704
Spleen 94.203 110.134 1.169
Lung 102.941 103.642 1.007
Ovary and
uterus
84.217 104.152 1.237
Kidney 117.103 144.046 1.230
aAUC of the tissues, 0 to 8 h.
bThe ratio was AUCPolysorbate 80/Phospholipid mixed micelles/AUCPolysorbate80 micelles.
Figure 5 Mean concentration-time profiles of DTX in (A) heart, (B) liver, (C) spleen, (D) lung, (E) ovary/uterus, and (F) kidney, and
following intravenous administration of a single 75 mg/m
2 dose of DTX Polysorbate 80 micelles injection and DTX Polysorbate 80/
Phospholipid mixed micelles injection to mice (Each point represents the Mean ± SD of four mice.).
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Page 9 of 12This is very important when the vesicles need to avoid
the recognition of RES [18].
Although DTX-loaded Polysorbate 80/Phospholipid
mixed micelles achieved the mean diameter of 13.89 ±
3.52 nm, which is still safely smaller than most of the
drug vesicles. In addition, the TEM picture showed that
the mixed micelles had a rod-like shape. It is different
from the sphere morphology of liposomes prepared with
Phospholipids. By close observation of the picture,
bright and dark regions were observed in these mixed
micelles further. The bright region might be attributed
to the hydrophilic micelle shell, and the dark region
might respond to the hydrophobic core of micelle with
DTX. This core-shell structure of mixed micelles plays
an important role in avoiding RES and providing long
circulation time in blood [19].
The bioanalysis methods of DTX have been performed
using HPLC with ultraviolet (UV) or mass spectrometric
(MS) detection, or by enzyme-linked immunosorbent
assays [20]. The lowest quantitation limits of these tech-
niques were 10, 0.2, and 0.3 ng/mL, respectively. Since
chromatographic methods are, in general, more selective
and may provide information on drug metabolism,
HPLC is usually preferred to immunoassays. Although
MS detection is by far superior to UV detection, this
technique is at the disposal of few laboratories or hospi-
tals only, due to the high costs of the required equip-
ment. For these reasons, the analysis method of DTX by
means of HPLC with UV detection is generally consid-
ered a first choice for pharmacokinetic and tissue distri-
bution studies in this work. According to the previous
reports, a relatively good resolution was achieved for
DTX by use of a manual pre-processing solid-phase
extraction (SPE) procedure [21]. Herein, we developed a
simpler reverse-phase HPLC analysis method of DTX
concentration in plasma by use of a simpler liquid-liquid
extraction instead of a SPE procedure, further with a
HPLC mobile phase polarity regulator of tetrahydro-
furan, and a HPLC mobile phase pH value slight regula-
tor of acetic acid for a better optimization separation of
DTX. Using this system, the retention time for DTX in
rats plasma and mice tissue were approximately 10.7
and 11.2 min, respectively, with good resolution and
without any interference from endogenous plasma con-
stituents or DTX metabolites at these retention times.
The total run time needed is only 13 min.
The pharmacokinetic profiles of the DTX encapsu-
lated in the Polysorbate 80 micelles and Polysorbate 80/
Phospholipid mixed micelles were consistent with a
three-compartment pharmacokinetic model. The initial
rapid decline represents distribution to the peripheral
compartments and the late (terminal) phase is due, in
part, to a relatively slow efflux of DTX from the periph-
eral compartment. These were agreeing with the pre-
vious research [22]. In addition, the results of hemolysis
test and DTX plasma protein binding test showed that
there is no obvious change to the blood distribution
procedure of DTX captured in these micelles. All of
these indicated that the encapsulation of DTX in Poly-
sorbate 80/Phospholipid mixed micelles had not led to a
change of pharmacokinetics.
To our knowledge, very little information has been
published about the tissue distribution of DTX. In this
work, the higher concentrations of DTX following intra-
venous administration in mice were found in the kidney,
lung, and spleen than in plasma. The DTX concentra-
tion in the brain was very low, many brain samples
could not be accurately measured because the concen-
tration was lower than the limit of quantitation. These
were consistent with the work reported by Zhao et al.
[23]. Both the ovaries and uterus are too small to deter-
mine individually, so in this study, we placed them
together. An interesting result in this work was that
Polysorbate 80/Phospholipid mixed micelles increased
the distribution of DTX in the ovaries and uterus, kid-
ney, spleen, liver, and heart significantly, especially in
liver. This show that DTX filled into the core of the
mixed micelles get a preferred distribution in the organs
rich in blood [24], not in plasma, this may due to the
superior cell membrane biocompatibility of Phospholipid
molecule. Because DTX had been proved effective in the
Table 5 Hemosysis test of DTX-loaded Polysorbate 80 micelles and DTX-loaded Polysorbate 80/Phospholipid mixed
micelles
N o . 123456 7
HR of DTX-loaded Polysorbate 80 micelles (%) 1.046 1.535 1.839 2.260 3.745 0 100
HR of DTX-loaded Polysorbate 80/Phospholipid mixed micelles 0.928 1.181 1.552 2.075 2.480 0 100
(%)
Results were shown on mean ± SD (n = 3).
Table 6 The binding efficiencies (%) between DTX and
the proteins in plasma (n =3 )
No. Polysorbate80
micelles
Polysorbate80/lecithin mixed
micelles
Mean ±
SD
84.21 ± 2.21 86.05 ± 2.41
P 0.3841
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Page 10 of 12treatment of tumor in these organs, therefore these
results may improve the feasibility of reducing the
dosage and intensifying the tumor tissues targeting abil-
ity of DTX. In addition, in case being encapsulated in
Polysorbate 80 single component micelles or Polysorbate
80/Phospholipid mixed micelles, there is no evidence
show that DTX have the preferential accumulation in
RES tissues (spleen, lung, and liver etc.) compared with
other tissues.
Conclusion
A mixed micelle drug delivery system based on Polysor-
bate 80 and Phospholipid was developed and character-
ized as an effective alternative to DTX clinical
preparation (Taxotere
®). Our results demonstrated that
the mixed micelles might efficiently load, protect, and
retain DTX in biological environment. As a result,
incorporating DTX in Polysorbate 80/Phospholipid
mixed micelles can increase the drug residence amount
in kidney, spleen, ovary and uterus, heart, and liver, and
at the same time keep more consistent pharmacokinetics
compared with Polysorbate 80 single component
micelles (Taxotere
®). These results suggested that Poly-
sorbate 80/Phospholipid mixed micelle formulation can
provide useful alternative dosage forms for clinical intra-
venous administration of DTX, and appear to be the
best possible approach, which could bypass the limita-
tion of current delivery system and provide a desirable
therapeutic efficacy of DTX. A study on the formative
mechanism of this drug loaded mixed micelles is under
way in our lab.
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